NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE27254 Query DataSets for GSE27254
Status Public on Nov 22, 2012
Title Role of Aldoketoreductases and Other Doxorubicin Pharmacokinetic Genes in Doxorubicin Resistance, DNA binding, and Subcellular Localization
Organism Homo sapiens
Experiment type Expression profiling by array
Summary Objective: To assess the role of aldoketoreductases and other doxorubicin pharmacokinetic or pharmacogenomic genes in doxorubicin cytotoxicity, resistance, DNA binding activity, and subcellular localization, Methods: We conducted a whole genome microarray study to identify differences in between doxorubicin-sensitive MCF-7cc cells and doxorubicin-resistant MCF-7Dox2-12 cells in terms of their expression of genes related to doxorubicin pharmacokinetics or pharmacodynamics. Targets were then validated by pharmacologic inhibition in conjunction with drug metabolite profiling, drug localization, drug cytotoxicity, and drug DNA binding studies. Results: 2063 differentially expressed transcripts were identified, including 17% and 43% of genes or gene families associated with doxorubicin pharmacokinetics or pharmacodynamics (p values of significance of 0.05 and <0.0001, respectively). The largest changes in the expression of genes associated with doxorubicin pharmacokinetics and pharmacodynamics were chiefly among the aldo-keto reductases (AKRs) Akr1c2, Akr1c3 and Akr1b10 which convert doxorubicin to doxorubicinol. We observed that doxorubicinol exhibits dramatically reduced drug toxicity, reduced drug DNA-binding activity, and altered drug subcellular localization to lysosomes. Pharmacologic inhibition of these AKRs in MCF-7Dox2-12 cells restored drug cytotoxicity, and drug localization to the nucleus. Conclusion: These findings demonstrate the utility of using curated pharmacokinetic and pharmacodynamic knowledgebases to identify highly relevant genes associated with doxorubicin resistance. The products of one or more of these genes could effectively be shown to alter the drug’s properties, while inhibiting them restored drug DNA binding, cytotoxicity, and subcellular localization.
 
Overall design Doxorubicin resistant cell lines of breast MCF-7 cells were generated for gene expression profilling. Two colour microarray of Agilent whole human genome nucleotide arrays was conducted with four labelling replicates of both forward and reverse labellings plus another set of 8 arrays with forward labelling. Sixteen arrays were used for this experiments. The co-cultured control cells MCF-7cc12 was generated by parallel selection process in the absence of drug.
 
Contributor(s) Heibein AD, Guo B, Sprowl JA, MacLean DA, Parissenti AM
Citation(s) 22938713
Submission date Feb 11, 2011
Last update date Feb 22, 2018
Contact name Baoqing Guo
E-mail(s) bguo@amric.ca
Phone 705 522 6237
Organization name Advanced Medical Research Institute of Canada
Department Tumor Biology
Street address 41 Ramsey Lake Road
City Sudbury
State/province ON
ZIP/Postal code P3E 5J1
Country Canada
 
Platforms (1)
GPL4133 Agilent-014850 Whole Human Genome Microarray 4x44K G4112F (Feature Number version)
Samples (16)
GSM673809 MCF-7Dox2-12 vs MCF-7cc12 forward labeling set 1 replicate 1
GSM673810 MCF-7Dox2-12 vs MCF-7cc12 forward labeling set 1 replicate 2
GSM673811 MCF-7Dox2-12 vs MCF-7cc12 forward labeling set 1 replicate 3
Relations
BioProject PRJNA137203

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE27254_MCF-7Dox2-12_vs_MCF-7cc_4-way_ANOVA_analysis.txt.gz 1.9 Mb (ftp)(http) TXT
GSE27254_RAW.tar 250.7 Mb (http)(custom) TAR (of TXT)
Processed data included within Sample table
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap